The estimated Net Worth of Christopher G. Hayes is at least $713 Mille dollars as of 26 August 2024. Mr. Hayes owns over 35,713 units of Verrica Pharmaceuticals Inc stock worth over $204,142 and over the last 5 years he sold VRCA stock worth over $508,971. In addition, he makes $0 as General Counsel, Corporate Secretary e Chief Legal Officer at Verrica Pharmaceuticals Inc.
Sign up
Mr. Hayes VRCA stock SEC Form 4 insiders trading
Christopher has made over 7 trades of the Verrica Pharmaceuticals Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 35,713 units of VRCA stock worth $93,211 on 26 August 2024.
The largest trade he's ever made was selling 35,713 units of Verrica Pharmaceuticals Inc stock on 26 August 2024 worth over $93,211. On average, Christopher trades about 10,820 units every 91 days since 2020. As of 26 August 2024 he still owns at least 105,773 units of Verrica Pharmaceuticals Inc stock.
You can see the complete history of Mr. Hayes stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Christopher Hayes biography
Christopher G. Hayes serves as General Counsel, Corporate Secretary, Chief Legal Officer of the Company. Prior to joining our company, Mr. Hayes was a practicing attorney and was the owner of the Law Office of Christopher G. Hayes from 2001 to September 2018. Prior to that, Mr. Hayes was a partner at boutique complex litigation firm with offices in Philadelphia, PA and New York, NY, where he practiced for 10 years in state and federal courts. His experience includes corporate and securities law and litigation, commercial transactions, contract administration, antitrust law and complex litigation, corporate development and governance, and labor and employment law. Mr. Hayes received a B.A. in economics from Villanova University and a J.D. from The Catholic University of America, Columbus School of Law.
How old is Christopher Hayes?
Christopher Hayes is 56, he's been the General Counsel, Corporate Secretary e Chief Legal Officer of Verrica Pharmaceuticals Inc since 2018. There are 4 older and 8 younger executives at Verrica Pharmaceuticals Inc. The oldest executive at Verrica Pharmaceuticals Inc is Lawrence Eichenfield, 62, who is the Director.
What's Christopher Hayes's mailing address?
Christopher's mailing address filed with the SEC is C/O VERRICA PHARMACEUTICALS INC., 44 WEST GAY STREET, SUITE 400, WEST CHESTER, PA, 19380.
Insiders trading at Verrica Pharmaceuticals Inc
Over the last 6 years, insiders at Verrica Pharmaceuticals Inc have traded over $8,200,904 worth of Verrica Pharmaceuticals Inc stock and bought 11,305,854 units worth $62,586,502 . The most active insiders traders include Advisors Llcperceptive Life..., Paul B Manning e John A Iii Stalfort. On average, Verrica Pharmaceuticals Inc executives and independent directors trade stock every 20 days with the average trade being worth of $213,456. The most recent stock trade was executed by Christopher G. Hayes on 26 August 2024, trading 35,713 units of VRCA stock currently worth $93,211.
What does Verrica Pharmaceuticals Inc do?
verrica pharmaceuticals inc., a clinical stage medical dermatology company, develops and commercializes dermatological treatments in the united states. the company's lead product candidate include vp-102 that is in phase iii clinical trial for the treatment of molluscum contagiosum; in phase ii clinical trial for the treatment of common warts; and completed phase i clinical trial for the treatment of genital warts. it is also developing cantharidin-based product candidate, vp-103 for the treatment of plantar warts. the company has a license agreement with lytix biopharma as to develop and commercialize ltx-315 for dermatologic oncology indications. verrica pharmaceuticals inc. was founded in 2013 and is headquartered in west chester, pennsylvania.
What does Verrica Pharmaceuticals Inc's logo look like?
Complete history of Mr. Hayes stock trades at Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc executives and stock owners
Verrica Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Ted White,
President, Chief Executive Officer, Director -
Brian Davis,
Chief Financial Officer -
Joe Bonaccorso,
Chief Commercial Officer -
Ted White,
Pres, CEO & Director -
Dr. Gary Goldenberg M.D.,
Chief Medical Officer -
Mark Prygocki,
Independent Director -
Gary Goldenberg,
Chief Medical Officer -
Craig Ballaron,
Independent Director -
Sean Stalfort,
Director -
Diem Nguyen,
Director -
Lawrence Eichenfield,
Director -
Bradley Catalone,
Head of Drug Development -
Patrick Burnett,
Chief Medical Officer -
Christopher Hayes,
General Counsel, Corporate Secretary, Chief Legal Officer -
Paul Manning,
Chairman of the Board -
Dr. Bradley J. Catalone MBA, Ph.D.,
Head of Drug Devel. -
Eugene Scavola,
Exec. VP of Technical Operations -
Joe Bonaccorso,
Chief Commercial Officer -
Christopher G. Hayes,
Chief Legal Officer, Sec. & Gen. Counsel -
P. Terence Kohler,
Chief Financial Officer -
Matt Davidson,
10% owner -
John A Iii Stalfort,
Director -
Glenn A Oclassen,
Director -
Advisors Llcperceptive Life...,
-
Linda Palczuk,
Chief Operating Officer -
Chris Degnan,
Chief Financial Officer -
Terry Kohler,
CHIEF FINANCIAL OFFICER